Doris Duke Foundation Offers Awards Program

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

NEW YORK-The Doris Duke Charitable Foundation has established the Doris Duke Distinguished Clinical Scientist Award Program, a $12 million initiative to fund the research teams of four eminent scientists studying cancer, AIDS, heart disease, and sickle cell anemia and related blood disorders. Recipients of the first awards are expected to be named in late 1999.

NEW YORK—The Doris Duke Charitable Foundation has established the Doris Duke Distinguished Clinical Scientist Award Program, a $12 million initiative to fund the research teams of four eminent scientists studying cancer, AIDS, heart disease, and sickle cell anemia and related blood disorders. Recipients of the first awards are expected to be named in late 1999.

Each funded researcher will receive a grant of up to $600,000 a year for 5 years. Awardees will focus on “bench to bedside” research. They will be expected to play a major role in their institutions in bridging the gap between bench science and clinical research and promote the development of a new generation of clinical scientists.

The Foundation will solicit application submissions from senior clinical scientists at the 25 medical schools that receive the greatest amount of support from the National Institutes of Health in each of the four disease areas.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.